Human medicines European public assessment report (EPAR): Eyluxvi, aflibercept, Date of authorisation: 15/09/2025, Status: Authorised

The approval of Eyluxvi, a biosimilar to aflibercept, for various eye conditions in Europe signifies increased market competition, expanded treatment options, and potentially lower costs for patients. This event showcases Alteogen's success in biosimilar development, offering biotech/pharma professionals insights into market dynamics and the growing importance of biosimilars in improving healthcare accessibility.